Vaduz Liechtenstein Charlevoix Sovereign Strategic Investment Fund
Additional shared vehicles: Silver Lake Technology Investors VIII (2025 Vintage) · SV Biotech Crossover Opportunities Fund, L.P. (2025 Vintage)
$22.1B Total AUM · Institutional LP profile covering 24 historical fund disclosure records ($1.30B parsed USD across disclosed rows) across disclosed strategy exposure in Buyout, Venture Capital, Private Equity, Real Estate, Private Credit (investment geography mandates are evaluated separately from LP headquarters). 5 complete primary source trails are open below without registration.
Showing 5 open preview records out of 24 total tracked records (+19 gated pilot rows). Click Inspect Source on any row to view field-level substantiation, table headers/units, and archived page excerpts without login.
| Disclosed Fund / Vehicle | Strategy | Fund Vintage | Disclosed Amount | Disclosed Performance | Primary Source Trail |
|---|---|---|---|---|---|
| Tenex Capital Partners III, L.P. | Buyout | 2025 |
$63.0M
General webpage link · Exact filing & amount pending · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · Allocator Webpage (Unanchored URL) |
| SV Life Sciences Fund VI, L.P. | Buyout | 2025 |
$60.0M
General webpage link · Exact filing & amount pending · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · Allocator Webpage (Unanchored URL) |
| Silver Lake Technology Investors VIII | Buyout | 2025 |
$58.8M
General webpage link · Exact filing & amount pending · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · Allocator Webpage (Unanchored URL) |
| SV Biotech Crossover Opportunities Fund, L.P. | Buyout | 2025 |
$47.8M
General webpage link · Exact filing & amount pending · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · Allocator Webpage (Unanchored URL) |
| SV7 Impact Medicine Fund, L.P. | Buyout | 2025 |
$46.5M
General webpage link · Exact filing & amount pending · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · Allocator Webpage (Unanchored URL) |
Tracked separately from historical commitments: active RFPs/searches, board pacing plans, leadership/CIO updates, and retained gatekeeper consultants.
Carrabassett Cape Fear Bellingham Mutual & Casualty Insurance General Account (Insurance Company, $22.1B AUM): Disclosed FY2025-2026 Private Markets Pacing & Allocation Update (PE Target 8.0% vs. 5.0% Actual; $663.0M Unallocated Target Bandwidth). Active FY2025–2026 Private Markets Pacing: Deploying ~$298M–$564M/yr across 4–8 institutional GP fund commitments (Target PE Allocation 8.0% vs 5.0% actual on $22.1B total assets). Gatekeeper / Intake Conduit: Segal Marco Advisors.
Forward-looking board pacing or target-allocation policy update · Recorded 2025-03-02
Board-Approved Pacing Plans, Active RFPs & Target-vs-Actual Allocation Gap
Join waitlist for pacing dossier →
Retained Private Markets Advisors & Emerging-Manager Search Conduits
Join waitlist for consultant map →
CIO, Private Markets Officers & Official Pitch Intake Guidance
Join waitlist for team directory →
You are viewing 5 open public preview records (out of 24 total tracked records for Carrabassett Cape Fear Bellingham Mutual & Casualty Insurance General Account) with zero-registration primary source trails. Join the early-access waitlist to request pilot access:
Enter your firm email to request pilot onboarding for Carrabassett Cape Fear Bellingham Mutual & Casualty Insurance General Account and our interactive GP workspace.
Thank you for joining the Prilago early-access waitlist! We will reach out with pilot access details for your firm.
Carrabassett Cape Fear Bellingham Mutual & Casualty Insurance General Account is categorized under Insurance Company (Regional Roadshow Hub: Massachusetts / New England; Headquarters: Farmington, ME). Across 24 historical disclosure records tracked on Prilago ($1.30B total parsed USD across disclosed rows), the median disclosed amount is $56.0M (range: $42.4M to $66.0M).
Carrabassett Cape Fear Bellingham Mutual & Casualty Insurance General Account has disclosed records across Buyout, Venture Capital, Private Equity, Real Estate, Private Credit. Open preview records include Tenex Capital Partners III, L.P. (2025 Vintage), SV Life Sciences Fund VI, L.P. (2025 Vintage), Silver Lake Technology Investors VIII (2025 Vintage), SV Biotech Crossover Opportunities Fund, L.P. (2025 Vintage).
Records for Carrabassett Cape Fear Bellingham Mutual & Casualty Insurance General Account cite primary public disclosures (Allocator Webpage (Unanchored URL)), and visitors can inspect 5 open source trails on this profile without registration. Each source trail displays field-level substantiation status, distinguishing exact commitment schedules from carrying-value or fee tables. Forward-looking active searches, RFPs, pacing plans, and governance updates are separated from historical disclosures.
General Partners can join the early-access waitlist on https://prilago.com/lp/carrabassett-cape-fear-bellingham-mutual-and-casualty-insurance-general-account or test fund suitability in the interactive read-only demo at https://prilago.com/demo.
In Prilago's bilateral commitment graph, Carrabassett Cape Fear Bellingham Mutual & Casualty Insurance General Account shares resolved underlying fund vehicles with 557 institutional LPs across 24 shared vehicles (shared fund exposure represents a potential introduction path and does not prove LPAC seat overlap or personal acquaintance). Top shared-fund peers include Vaduz Liechtenstein Charlevoix Sovereign Strategic Investment Fund (12 shared vehicles, e.g. SV Life Sciences Fund VI, L.P. (2025 Vintage)), Fairfield County Hopewell Pendleton Institutional Outsourced CIO & Wealth Advisory (12 shared vehicles, e.g. Silver Lake Technology Investors VIII (2025 Vintage)), Blackstone Valley Gulf Breeze Holmberg Institutional Outsourced CIO & Wealth Advisory (11 shared vehicles, e.g. SV Biotech Crossover Opportunities Fund, L.P. (2025 Vintage)).